Re: Additional Reports of Exempt Distribution

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7698 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Additional Reports of Exempt Distribution

in response to

Re: Additional Reports of Exempt Distribution

Toinv

posted on Jul 25, 2023 02:48AM

Toinv - That's the way I understand it.

The vary high ORR in the NUT Midline trials is also something to pay close attention to.